US20090081139A1 - Water-based delivery systems - Google Patents

Water-based delivery systems Download PDF

Info

Publication number
US20090081139A1
US20090081139A1 US12/082,406 US8240608A US2009081139A1 US 20090081139 A1 US20090081139 A1 US 20090081139A1 US 8240608 A US8240608 A US 8240608A US 2009081139 A1 US2009081139 A1 US 2009081139A1
Authority
US
United States
Prior art keywords
delivery system
dihydroxypropyl
acid
hydroxyethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/082,406
Inventor
Thomas Skold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Laboratories LP
Original Assignee
Thomas Skold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Skold filed Critical Thomas Skold
Priority to US12/082,406 priority Critical patent/US20090081139A1/en
Publication of US20090081139A1 publication Critical patent/US20090081139A1/en
Assigned to GALDERMA LABORATORIES, INC. reassignment GALDERMA LABORATORIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLLAGENEX PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Definitions

  • the present invention relates to a novel topical and mucosal delivery systems for drugs or any other active substance.
  • the main demands on human skin are to prevent loss of water, and to prevent water and other matter of the environment from entering the body indiscriminately.
  • the human skin thus forms a selectively permissible physical barrier between the human body and its surroundings.
  • the barrier function has been shown to reside in the stratum corneum.
  • the stratum corneum is the topmost layer of the skin, and is built of corneocytes.
  • Corneocytes are cells that contain extensively cross-linked proteins, surrounded by a highly resistant cell envelope.
  • the corneocytes are embedded in a bed of specific lipid structures of long chain lipids. These long chain lipids are organized as bilamellar structures stacked on top of each other. The bilamellar structures fill the intercellular spaces between the corneocytes.
  • the skin has been described as a mosaic barrier model.
  • This model envisages barrier lipids to exist predominantly in crystalline (gel) form.
  • Such a form provides water impermeable domains, which are surrounded by so-called grain borders of lipids in a liquid crystalline state.
  • This arrangement provides an effective, water tight barrier that still allows a minute but controlled loss of water through the liquid crystalline interdomains. This controlled water loss is enough to keep the keratin of the stratum corneum hydrated.
  • the liquid character of the interdomain grain borders allows passage of hydrophilic and hydrophobic molecules on down-hill gradients, i.e. passage by passive diffusion.
  • Dermal delivery systems are compositions which deliver active substances to, or through, the skin. These compositions typically contain skin permeation enhancers. Permeation enhancers may induce structural transformations of the bilamellar structure in the liquid crystalline interdomain regions, and thus promote transdermal delivery of, for example, pharmacological substances.
  • Typical dermal delivery systems have an alcohol or petroleum base, with little consideration given to the biological properties of the vehicle itself.
  • emulsified fatty acids can inherit certain detergent properties if their structure is significantly altered from those in the normal skin.
  • the detergent properties can lead to disruption of the normal barrier function, which is counteractive to the potential benefit of the delivery system. Disruption of the normal barrier function often causes the stratum corneum to lose its natural potential to function properly as a barrier. As a result, the skin becomes either too dry or too permeable to environmental substances.
  • barrier ointments Other conventional delivery systems that are thought to protect the skin from harmful substances are barrier ointments.
  • the purpose of barrier ointments is to provide a film, and thereby create a layer which is impermeable to environmental substances. Due to the impermeability, though, these ointments both increase the body temperature of the treated body part, as well as prevent perspiration, and thus render an uncomfortable sensation.
  • the dermal delivery systems described above are not formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function.
  • the invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, and a ceramide.
  • the delivery system also comprises at least one skin lipid precursor.
  • the invention relates to delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles.
  • This delivery system can also comprise at least one skin lipid precursor.
  • FIG. 1 is a diagram showing the gas spheres, lipid particles, vesicles and hydrophilic phase of the delivery systems.
  • FIG. 2 is a diagram showing the components of the gas spheres of the delivery systems.
  • FIG. 3 is a diagram showing the components of the lipid particles and of the vesicles of the delivery systems.
  • FIG. 4 is a diagram showing the location of active substances within the various microcompartments of the delivery systems.
  • the present invention provides an improved topical delivery system (skin preparation) formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function. Additionally, the topical delivery system of the present invention provides unique skin barrier restoration properties.
  • the topical delivery system of the present invention is a water-based formulation comprising hydrophilic and lipophilic components.
  • the delivery system comprises a water content exceeding 50%, such as more than 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 85%, 87%, 90%, 94%, 95% and 98%.
  • the water content is between 60-80%, more preferably, between 70 and 80%.
  • the topical delivery system is preferably designed, in its choice and composition of lipids, to resemble the normal lipid organization of the stratum corneum (horny layer), as much as possible.
  • the system blends with the lipids naturally present in the stratum corneum, and easily penetrates the lipid bilayer of the skin. In doing so, the system carries along with it one or more active substances to be administered.
  • the system enhances penetration of active substances into and/or through the stratum corneum, while the normal barrier properties of the stratum corneum are left intact, and/or are even functionally enhanced.
  • the lipophilic component (i.e. lipids) of the system comprises fatty acids, cholesterol and a ceramide/phospholipid portion.
  • the lipids are similar to those which make up the normal stratum corneum.
  • the preferred ratio of the ceramide/phospholipid portion:cholesterol:fatty acid is in the range of approximately 2:1:1.5 to approximately 2.95:0.5:0.5. Preferably, for example, the ratio is approximately 2:1:1; more preferably the ratio is approximately 2.35:1:1.
  • the fatty acids of the present invention can be any fatty acid, mixtures of fatty acids, salts of fatty acids, or mixtures of fatty acids and salts of fatty acids.
  • the fatty acids can be saturated or unsaturated. Additionally, the fatty acids can comprise precursors of fatty acids. In a preferred embodiment, the fatty acids comprise ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, or twenty-four carbon atoms, or any mixture of such fatty acids. A fatty acid mixture with a predominant portion of fatty acids which comprise a chain of sixteen or eighteen carbon atoms is most preferred.
  • the delivery system can be prepared from a mixture of fatty acids of the following composition: at most about 2% of a component comprising a chain of fourteen carbon atoms, between about 47 and about 52% of a component comprising a chain of sixteen carbon atoms, between about 43 and about 48% of a component comprising a chain of eighteen carbon atoms, and at most about 1% of a component comprising a chain of twenty carbon atoms.
  • Suitable saturated fatty acids for use in the delivery system include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid.
  • suitable unsaturated fatty acids include oleic acid, palmitoleic acid, linoleic acid, linolenic acid, and arachidonic acid.
  • the delivery system contains an essential portion, such as about 90%, of such fatty acids.
  • the preferred fatty acids are the essential fatty acids (EFAs).
  • EFAs are essential for the plasma membrane formation of all cells. In keratinocytes, EFA deficiency makes cells hyperproliferative. Supplementation of EFAs reverses the hyperproliferation. EFAs also enhance lipid biosynthesis of the epidermis and provide lipids for the barrier formation of the epidermis.
  • the essential fatty acids are preferably chosen from linoleic acid, ⁇ -linolenic acid, homo- ⁇ -linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid, and mixtures thereof.
  • the delivery system also comprises cholesterol, or derivatives of cholesterol such as, for example, lipid esters of cholesterol.
  • the ceramide/phospholipid portion can comprise 100% ceramide, 100% phospholipids, or any other percent combination of ceramide and phospholipids.
  • the ceramide/phospholipid portion can comprise 95% ceramide and 5% phospholipids, 90% ceramide and 10% phospholipids, 85% ceramide and 15% phospholipids, or 80% ceramide and 20% phospholipids.
  • the ceramide component of the delivery system can be any ceramide or any mixture of ceramides.
  • ceramides include pseudoceramides and neoceramides.
  • the ceramide may be any of ceramide 1-7; and/or mixtures thereof.
  • Some specific examples of ceramides include ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, cerebrosides and ceramide 6B.
  • pseudoceramides include:
  • the phospholipid component may contain any phospholipid or mixtures of phospholipids.
  • the phospholipid component comprises phosphatidycholine (PC).
  • PC phosphatidycholine
  • Other examples of phospholipids include distearoylphosphatidylcholine (DSPC 18), phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
  • the phospholipid component can comprise one or more lysophospholipids.
  • Lysophospholipids are single chain phospholipids.
  • Examples of lysophospholipids include lysophosphatidylcholines, such as monopalmitoylphosphatidylcholine (MPPC); lysophosphatidylglycerols; lysophosphatidylethanolamines; lysophosphatidylinositols; lysophosphatidylserines; and lysophosphatidic acid. Mixtures of different types of phospholipids and/or lysophospholipids can also be used.
  • MPPC monopalmitoylphosphatidylcholine
  • lysophosphatidylglycerols lysophosphatidylglycerols
  • lysophosphatidylethanolamines lysophosphatidylinositols
  • the present system also comprises skin lipid precursors.
  • the lipid precursors include any compound that promotes in situ cholesterol, ceramide or sphingolipid synthesis.
  • the preferred lipid precursors are mevalonic acid, which promotes in situ cholesterol synthesis; and 25-hydroxycholecalciferol, which promotes in situ ceramide synthesis in the skin.
  • Other preferred precursors are palmitoyl CoA and serine, which together are converted to 3-ketosphinganine, which promotes in situ ceramide synthesis in the skin.
  • the overall content of lipid in the system can be maintained in a range as low as approximately 2-20%. Therefore, the water content of the delivery system can be as high as 80-98%.
  • the high water content enables the skin to “breathe” normally, and enhances its ability to restore its normal barrier function rapidly.
  • lipid precursors useful in the present invention include, for example: acylceramides; deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxysalicylic acid, N-acetylcysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate,
  • an alkaline compound or buffer system
  • alkaline compounds include triethanolamine (TEA), sodium hydroxide, sodium acetate, and sodium bicarbonate.
  • buffer systems include carbonic acid/potassium carbonate, phosphoric acid/potassium phosphate, and acetic acid/sodium acetate.
  • the fatty acids of the final delivery system can be in a free state or can form a salt.
  • the portion of fatty acids which is in a free state is partially dependent on the pH of the formulation.
  • the level of free fatty acid increases as the pH of the formulation decreases.
  • the pH of the formulation can vary.
  • the pH of the formulation is about 6.5 to 7.8.
  • the delivery system comprises triethanolamine (TEA). It is preferred to adapt the molar ratio between the fatty acids and triethanolamine to enable a certain portion of the fatty acids in the final delivery system to form a triethanolaminium salt, while another portion of the acid exists as free fatty acid.
  • TAA triethanolamine
  • the delivery system is prepared from fatty acids and triethanolamine in which the molar ratio of the fatty acids to the triethanolamine is higher than about 2:1, preferably higher than about 3:1.
  • the delivery system comprises a combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and skin lipid precursors between about 2-20%.
  • a preferred low end of this range is about 2%, 3%, 4%, 5%, 6%, 7% or 8%.
  • a preferred high end of this range is about 13%, 14%, 15%, 16%, 17%, 18%, 19% and 20%.
  • the amounts of the components of the delivery system are as follows: fatty acid: 0.5-10%; cholesterol: 0.5-10%; a ceramide/phospholipid portion: 0.005-20%; and lipid precursors: 0.000001-10%.
  • the formulation does not contain any irritating ingredients.
  • irritating ingredients include alcohols, such as isopropanol and ethanol; short chain fatty acids; and detergents.
  • the formulation contains less than 10% alcohol, more preferably less than 5% alcohol, most preferably less than 1% alcohol, and optimally no alcohol.
  • the administered formulation easily penetrates the lipid bilayer of the skin.
  • the system creates a temporary and reversible state of enhanced atrophy among the lipid components of the bilayer.
  • the enhanced atrophy in itself then gives rise to either a) enhanced energy levels, wherein the energy could promote active transport of the to-be-carried substances into the skin, and/or b) creates naturally and reversibly occurring holes and disorganized patches in the lipid bilayer through which the active substances could then pass more easily.
  • the temporary disarray in the lipid bilayer will temporarily break up the organized structure of the bilayer and create micelles of lipids with areas between them, or surrounding them, through which lipophobic/hydrophilic substances and/or compositions can enter through the stratum corneum.
  • the lipid composition of the formulation resembles the natural lipid composition of the skin, the so introduced new lipids will after a short time of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer, and thus not permanently damage the barrier function of the skin.
  • the normal barrier function of the cornea stratum rapidly returns. (That is, the skin barrier restoration is rapid.)
  • the rapid return may be enhanced by the lipid precursors of the formulation.
  • the in situ promotion of cholesterol synthesis in the stratum corneum, the in situ promotion of ceramide synthesis in the stratum corneum, and/or the in situ promotion of sphingolipid synthesis in the stratum corneum may allow for the rapid skin barrier restoration.
  • a delivery system according to the present invention preferably comprises a combination of:
  • Fatty Acid C16-24
  • Phospholipid 0.5-10%
  • Cholesterol 0.5-7%
  • Lipid precursor 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7% (Not all components are present are 0%.)
  • Another preferred embodiment of the delivery system comprises:
  • Fatty Acid C16-24
  • Phospholipid 0.5-10%
  • Cholesterol 0.5-7%
  • Lipid precursor 0.000001-10% Mevalonic acid and/or 25-Hydroxycholecalciferol Ceramide 0.005%-7%
  • Glycerine 0.000001-10%
  • Propylene glycol 0-48%
  • PVP e.g., M weight 40.000
  • TEA TEA 0-3%
  • An even more preferred embodiment of the delivery system comprises:
  • the topical delivery system according to the present invention further comprises one or more cosmetically and/or therapeutically active substances.
  • Active substances are defined as agents other than emollients and other than ingredients that merely improve the physical characteristics of the formulation.
  • active substances include sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants and vitamins.
  • Therapeutically active substances include, but are not limited to, substances which treat conditions such as eczema, dry skin, itchy skin, fungal infection, acne, skin cancer, hair loss, louse infection, psoriasis, and skin lesions (i.e. wounds).
  • Therapeutically active substances also include substances for transdermal delivery, for example, interleukin, hormones, vaccines, nicotine, interferon, pain killers, peptides, proteins and vitamins.
  • Active substances also include steroid hormones.
  • Steroid hormones inhibit inflammation and hyperproliferation of the epidermis thus resulting in normalization of hypersensitive skin conditions.
  • steroid hormones include, bat are not limited to, glucocorticoids, androgens and estrogens.
  • sunscreens include those materials commonly employed to block ultraviolet light.
  • Illustrative compounds are derivatives of PABA, cinnamate and salicylate.
  • octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone also known as oxybenzone
  • Octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively.
  • the exact amount of sunscreen employed in the systems can vary depending upon the degree of protection desired from the sun's UV radiation.
  • vitamins examples include vitamin A and vitamin E, preferably in the form of an ester of a fatty acid, such as vitamin A palmitate (retinyl palmitate) and vitamin E linoleate (tocopheryl linoleate).
  • esters of vitamins A and E may also be utilized, such as any of the fatty acids mentioned above and below.
  • Preservatives may also be included in the formulations of the present invention. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroxyacetate and benzyl alcohol. Preservatives are typically used in amounts up to about 2% by weight of the formulation.
  • adjunct minor components may also be incorporated into the formulations of the present invention. These components may include thickeners, coloring agents, opacifiers and perfumes. For example, any thickening agent can be included in the formulation to adjust the viscosity of the formulation. Examples of suitable thickening agents include glycerol and xanthan gum. Some additional adjunct minor components include chalk, talc, Fullers earth, kaolin, starch, smectites clays, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, aluminium starch octenyl succinate and mixtures thereof. Amounts of these adjunct minor components may range anywhere from 0.001 up to 20% by weight of the formulation (i.e. composition).
  • the delivery system can be in any form, such as a cream, a lotion, a gel, and an aerosol foam.
  • the amount of certain adjunct minor components used in a particular formulation varies depending on the desired form of the delivery system, as would be known by a skilled artisan.
  • the amount of thickening agent used to prepare an aerosol foam formulation is about 10 to 20% of the amount used to prepare a cream formulation.
  • emulsifiers are added to an aerosol foam formulation, such as, for example, laureth 4.
  • the present invention provides a mucosal delivery system formulated to deliver a substance to, or through, a human mucous membrane without permanently disturbing the integrity of the mucous membrane.
  • the mucous membrane is the moist tissue that lines some organs and body cavities (such as nose, mouth, lungs, rectum, stomach and vagina) and secretes mucous.
  • the mucosal delivery system comprises the lipophilic and hydrophilic components, as described above. The particular formulations of the mucosal delivery systems are varied to accommodate the particular environment of the mucosa, as would be known by a skilled artisan.
  • the lipophilic components of the topical or mucosal delivery system form three types of particles: gas spheres, vesicles, and lipid particles. These three types of particles are within a hydrophilic phase (i.e. aqueous medium). See FIG. 1 .
  • the gas spheres are lipid monolayers that enclose air bubbles. These monolayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the outer surfaces of these gas spheres. See FIG. 2 . Preferably, these gas spheres are approximately 1 ⁇ m to approximately 500 ⁇ m in diameter.
  • the vesicles are lipid bilayers enclosing a hydrophilic core. These bilayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the inner and outer surfaces of the vesicles. See FIG. 3 .
  • the vesicles can range from approximately 0.02 ⁇ m to approximately 0.5 ⁇ m in diameter.
  • the lipid particles are lipid monolayers enclosing fatty acids. These monolayers are formed from the lipophilic components. See FIG. 3 .
  • the lipid particles are less than approximately 1 to approximately 150 ⁇ m in diameter.
  • the lipid particles may be in the form of individual lipid particles, or the lipid particles may aggregate to form crystals.
  • the various particles of the delivery system provide microcompartments with different properties. Due to these different microcompartments, the delivery system can be used to deliver both hydrophilic and lipophilic active substances.
  • a water soluble active substance can be located in the hydrophilic core of the vesicles, or can be located in the hydrophilic phase of the system.
  • a lipid soluble active substance can be located within the monolayer of the gas spheres, within the bilayer of the vesicles, or within the monolayer or within the core of the lipid particles. See FIG. 4 .
  • the delivery systems comprise three phases, i.e. a foam phase, a vesicle phase and a hydrophilic phase.
  • the foam phase comprises the gas spheres and the lipid particles.
  • the vesicle phase comprises the vesicles and the lipid particles.
  • the hydrophilic phase comprises water and hydrophilic components.
  • the delivery system is produced from three portions (i.e. fractions), in particular a hydrophilic portion and two lipophilic portions.
  • the two lipophilic portions comprise the lipophilic components as defined above. Both lipophilic portions are immersed in aqueous media.
  • One portion is made into the foam phase.
  • the other portion is made into the vesicle phase.
  • the foam phase portion and the vesicle phase portion can be in a ratio from about 1:7 to about 7:1.
  • the foam phase portion and the vesicle phase portion are approximately equal in amount.
  • the foam phase is formed by mixing the foam phase portion at about 65 to 85° C.
  • the pH is set to the range of about 5.5 to 8.2. The mixing is performed under conditions so as to allow gas spheres to form.
  • the vesicle phase is formed by gently mixing the vesicle phase portion at about 65 to 85° C.
  • the pH is set to the range of about 5.5 to 8.2.
  • the vesicle phase portion is homogenized. Homogenization can be accomplished with, for example, a high pressure homogenizer or a sonicator.
  • the pressure of the homogenizer can be set, for example, from about 10,000 to 40,000 psi.
  • the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
  • the lipid particles, and/or lipid particle crystals form as a by-product of the formation of the foam phase and vesicle phase.
  • up to 30% of the lipophilic components can be in the form of lipid particles and/or lipid particle crystals.
  • the hydrophilic phase is formed by mixing together water soluble components with water (i.e. hydrophilic portion).
  • water soluble components include propylene glycol, glycerol, polyvinylpyrrolidone, and thickeners, e.g., xanthan gum.
  • the foam phase, vesicle phase and hydrophilic phases are mixed together.
  • an equal amount of each phase is used in the formulation.
  • the foam phase, vesicle phase and hydrophilic phases can be mixed together in any order.
  • the foam phase and the vesicle phase can be first mixed together, and then the resulting mixture can be mixed with the hydrophilic phase.
  • the foam phase can be first mixed with the hydrophilic phase, and then the vesicle phase can be added.
  • One or more active substances can be added to the foam phase portion, the vesicle phase portion, the hydrophilic portion, or a combination of these portions.
  • the specific components of a formulation, and the formulation process can be varied to obtain delivery systems which allow for different rates of the release, and degrees of penetration, of active substance(s).
  • the phase of the system in which an active substance is placed affects release and penetration rates.
  • a major portion of the active substance is placed within the vesicle phase portion.
  • the size of the vesicles can be controlled via the formulation process. For example, during processing, as the homogenizing pressure and duration increases, the vesicle size decreases.
  • An additional factor which affects release and penetration rates is the type of phospholipids used in the formulation. For example, penetration can be enhanced by including a greater portion of unsaturated phospholipids within the formulation.
  • phospholipids which include elevated levels of surface active single chain agents enhance penetration.
  • Surface active single chain agents at about a level of 2% to 10% of the phospholipids are considered to be at an elevated level.
  • Examples of surface active agents are lysophospholipids
  • An example of a phospholipid formulation comprises 95% phosphatidylcholine and 1.2% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200 SH.
  • a phospholipid formulation which provides enhanced penetration comprises 95% phosphatidylcholine and 3% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200.
  • the concentration of free fatty acid is also an important parameter affecting penetration rates.
  • a relatively high level of free fatty acid enhances penetration of hydrophilic active substances.
  • Penetration rates can also be enhanced by the addition of certain adjuvants.
  • an anionic surfactant can be added to the foam phase portion.
  • incorporation of glyceryidilaurate into the vesicle bilayers creates more flexible vesicles which can enhance penetration.
  • Additional factors which affect release and penetration rates include: the ratio between the different lipid components; the ratio between the foam phase, the vesicle phase and the hydrophilic phase; and the ratio between the amounts of active substances within each phase.
  • the lipophilic components of the delivery system form only two of the above-defined particles. That is, the formulation comprises only the gas spheres and lipid particles; or the formulation comprises only the vesicles and lipid particles.
  • the delivery system is produced from a hydrophilic portion and a lipophilic portion.
  • the lipophilic portion is made either into the foam phase or the vesicle phase, as described above.
  • the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
  • the foam phase or vesicle phase is mixed with the hydrophilic phase.
  • an equal amount of either the foam phase or vesicle phase, and the hydrophilic phase is used in the formulation.
  • the phospholipid, cholesterol, palmitic acid and ceramide components are mixed together with water, and agitated at a temperature of 70-80° C.
  • the following additional components are added: mevalonic acid lactone, 25-hydroxycholecalciferol, propylene glycol, glycerine, PVP, TEA added along with water, and sodium hydroxide.
  • Sodium hydroxide is added to adjust viscosity and stabilize the formulation. Water is then added, and the formulation is agitated well. The formulation is then cooled down.
  • An active substance can be dissolved in both the lipid phase and/or the water phase, depending on the solubility and concentration of the active substance.
  • PC phosphatidylcholine
  • “Skinflux” is a blend product obtainable from Degussa Goldschmidt which contains: Ceramide 1, 3, 6II; Phytosphingosine; Cholesterol; Sodium Lauroyl Lactylate; Carbomer; and Xanthan Gum.
  • Mevalonic acid lactone is a lipid precursor for cholesterol/fatty acids.
  • 25-Hydroxycholecalciferol is a lipid precursor for ceramides
  • Xanthan Gum is a thickener (polysaccharide).
  • PHENONIP ® is a preservative and a blend of parabens.
  • a vesicle fraction Three fractions, a vesicle fraction, a foam fraction and a hydrophilic fraction, are first prepared separately, as described below. Each fraction weighs 3.3 kg. Then the three fractions are mixed together. The following tables show the percent amount of each component contributed by each fraction to the final formulation. Thus, for each component, the sum of the percent amounts of all the fractions is 100%.
  • Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g., Paraben mixture) 50% of total amount Xanthan gum 15% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 grams of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the vesicle fraction to the final formulation.
  • the components are mixed and heated to the temperature range of 65 to 85° C. while gently stirring.
  • the pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide.
  • the resulting mixture is then homogenized. Homogenization can be accomplished by, for example, a homogenizer set at a high pressure (e.g. 10,000 to 40,000 psi); or by a sonicator.
  • the size of the vesicles is partially dependent upon how long the resulting mixture is agitated. For example, to obtain an average vesicle size of 0.140 ⁇ m, the resulting mixture is agitated for 60 minutes at about 70° C. The mixture is then allowed to cool to below 40° C.
  • Percent Amount in Final Component Formulation Water 33% of total water Hydrogenated lecithins 50% of total amount Palmitic acid 50% of total amount Cholesterol 50% of total amount Mevalonic acid 50% of total amount Triethanol amine 50% of total amount Preservative (e.g. a paraben mixture) 50% of total amount Xanthan gum 7.5% of total amount Skinflux 33% of total amount 25-hydroxycholecalciferol 50% of total amount 5M sodium hydroxide 1.3 ml per 1000 g of water The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the foam fraction to the final formulation.
  • the components are mixed and heated to the temperature range of 65 to 85° C. while stirring.
  • the pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide.
  • the composition is mixed vigorously for 1 minute. Mixing can be done with ULTRATURRAX® from IKA Werke, Janke & Kunkel GmbH & Co KG (Staufen, Germany). The composition is then allowed to cool to below 40° C.
  • Percent Amount in Final Component Formulation Water 34% of total water Propylene glycol 100% of total amount Glycerol 100% of total amount Polyvinylpyrrolidone 100% of total amount Xanthan gum 77.5% of total amount Skinflux 34% of total amount 5M sodium hydroxide 3.0 ml per 1000 g of water
  • Percent Amount in Final Formulation indicates the percentage of each component which is contributed by the hydrophilic fraction to the final formulation.
  • the components are mixed and heated to the temperature range of 65 to 85° C. while stirring.
  • the pH is set to the range of 5.5 to 8.2 by use of sodium hydroxide. Once homogeneous, the composition is then allowed to cool to below 40° C.
  • the three fractions are mixed together in any order.
  • the foam fraction is added to the vesicle fraction and gently mixed.
  • the hydrophilic fraction is added.
  • the resulting mixture is gently blended for several minutes to obtain a homogeneous solution.
  • the delivery system of this example is in the form of a cream.
  • the total amount of xanthan gum in the final formulation is reduced from 2% to about 0.3%.
  • an emulsifier is added, such as laureth 4.
  • the emulsifier makes up about 0.7% of the final formulation.
  • enhancing skin barrier restoration can be measured by tape and/or acetone striping of stratum corneum skin lipid content before, during and after a treatment period with the present invention and other systems. Then HPLC analysis of skin lipid content of stratum corneum is conducted.

Abstract

The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Application No. 60/365,059, filed Mar. 13, 2002, which is incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to a novel topical and mucosal delivery systems for drugs or any other active substance.
    • BACKGROUND OF THE INVENTION
  • The main demands on human skin are to prevent loss of water, and to prevent water and other matter of the environment from entering the body indiscriminately. The human skin thus forms a selectively permissible physical barrier between the human body and its surroundings.
  • The barrier function has been shown to reside in the stratum corneum. The stratum corneum is the topmost layer of the skin, and is built of corneocytes. Corneocytes are cells that contain extensively cross-linked proteins, surrounded by a highly resistant cell envelope. The corneocytes are embedded in a bed of specific lipid structures of long chain lipids. These long chain lipids are organized as bilamellar structures stacked on top of each other. The bilamellar structures fill the intercellular spaces between the corneocytes.
  • To account for the skin's barrier properties, and for its selective hydrophilic and hydrophobic pathways, the skin has been described as a mosaic barrier model. This model envisages barrier lipids to exist predominantly in crystalline (gel) form. Such a form provides water impermeable domains, which are surrounded by so-called grain borders of lipids in a liquid crystalline state. This arrangement provides an effective, water tight barrier that still allows a minute but controlled loss of water through the liquid crystalline interdomains. This controlled water loss is enough to keep the keratin of the stratum corneum hydrated. The liquid character of the interdomain grain borders allows passage of hydrophilic and hydrophobic molecules on down-hill gradients, i.e. passage by passive diffusion.
  • Dermal delivery systems are compositions which deliver active substances to, or through, the skin. These compositions typically contain skin permeation enhancers. Permeation enhancers may induce structural transformations of the bilamellar structure in the liquid crystalline interdomain regions, and thus promote transdermal delivery of, for example, pharmacological substances.
  • Typical dermal delivery systems have an alcohol or petroleum base, with little consideration given to the biological properties of the vehicle itself. For example, emulsified fatty acids can inherit certain detergent properties if their structure is significantly altered from those in the normal skin. The detergent properties can lead to disruption of the normal barrier function, which is counteractive to the potential benefit of the delivery system. Disruption of the normal barrier function often causes the stratum corneum to lose its natural potential to function properly as a barrier. As a result, the skin becomes either too dry or too permeable to environmental substances.
  • Other conventional delivery systems that are thought to protect the skin from harmful substances are barrier ointments. The purpose of barrier ointments is to provide a film, and thereby create a layer which is impermeable to environmental substances. Due to the impermeability, though, these ointments both increase the body temperature of the treated body part, as well as prevent perspiration, and thus render an uncomfortable sensation.
  • The dermal delivery systems described above are not formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function.
    • SUMMARY OF THE INVENTION
  • In one embodiment, the invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, and a ceramide. In another embodiment, the delivery system also comprises at least one skin lipid precursor.
  • In an additional embodiment, the invention relates to delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles. This delivery system can also comprise at least one skin lipid precursor.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 is a diagram showing the gas spheres, lipid particles, vesicles and hydrophilic phase of the delivery systems.
  • FIG. 2 is a diagram showing the components of the gas spheres of the delivery systems.
  • FIG. 3 is a diagram showing the components of the lipid particles and of the vesicles of the delivery systems.
  • FIG. 4 is a diagram showing the location of active substances within the various microcompartments of the delivery systems.
    •  DETAILED DESCRIPTION OF INVENTION
  • The present invention provides an improved topical delivery system (skin preparation) formulated to deliver a substance to, or through, the human skin without permanently disrupting the stratum corneum's natural barrier function. Additionally, the topical delivery system of the present invention provides unique skin barrier restoration properties.
  • All percentages given below are indicated in percent by weight. All numbers are approximate.
  • The topical delivery system of the present invention is a water-based formulation comprising hydrophilic and lipophilic components. In a preferred embodiment, the delivery system comprises a water content exceeding 50%, such as more than 55%, 60%, 65%, 70%, 75%, 76%, 77%, 78%, 79%, 80%, 85%, 87%, 90%, 94%, 95% and 98%. Preferably, the water content is between 60-80%, more preferably, between 70 and 80%.
  • The topical delivery system is preferably designed, in its choice and composition of lipids, to resemble the normal lipid organization of the stratum corneum (horny layer), as much as possible. Upon administration, the system (formulation) blends with the lipids naturally present in the stratum corneum, and easily penetrates the lipid bilayer of the skin. In doing so, the system carries along with it one or more active substances to be administered. The system enhances penetration of active substances into and/or through the stratum corneum, while the normal barrier properties of the stratum corneum are left intact, and/or are even functionally enhanced.
  • The lipophilic component (i.e. lipids) of the system comprises fatty acids, cholesterol and a ceramide/phospholipid portion. The lipids are similar to those which make up the normal stratum corneum. The preferred ratio of the ceramide/phospholipid portion:cholesterol:fatty acid is in the range of approximately 2:1:1.5 to approximately 2.95:0.5:0.5. Preferably, for example, the ratio is approximately 2:1:1; more preferably the ratio is approximately 2.35:1:1.
  • The fatty acids of the present invention can be any fatty acid, mixtures of fatty acids, salts of fatty acids, or mixtures of fatty acids and salts of fatty acids. The fatty acids can be saturated or unsaturated. Additionally, the fatty acids can comprise precursors of fatty acids. In a preferred embodiment, the fatty acids comprise ten, twelve, fourteen, sixteen, eighteen, twenty, twenty-two, or twenty-four carbon atoms, or any mixture of such fatty acids. A fatty acid mixture with a predominant portion of fatty acids which comprise a chain of sixteen or eighteen carbon atoms is most preferred.
  • For example, the delivery system can be prepared from a mixture of fatty acids of the following composition: at most about 2% of a component comprising a chain of fourteen carbon atoms, between about 47 and about 52% of a component comprising a chain of sixteen carbon atoms, between about 43 and about 48% of a component comprising a chain of eighteen carbon atoms, and at most about 1% of a component comprising a chain of twenty carbon atoms.
  • Examples of suitable saturated fatty acids for use in the delivery system include lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, and lignoceric acid. Examples of suitable unsaturated fatty acids include oleic acid, palmitoleic acid, linoleic acid, linolenic acid, and arachidonic acid. Preferably, the delivery system contains an essential portion, such as about 90%, of such fatty acids.
  • The preferred fatty acids are the essential fatty acids (EFAs). EFAs are essential for the plasma membrane formation of all cells. In keratinocytes, EFA deficiency makes cells hyperproliferative. Supplementation of EFAs reverses the hyperproliferation. EFAs also enhance lipid biosynthesis of the epidermis and provide lipids for the barrier formation of the epidermis. The essential fatty acids are preferably chosen from linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid, and mixtures thereof.
  • The delivery system also comprises cholesterol, or derivatives of cholesterol such as, for example, lipid esters of cholesterol.
  • The ceramide/phospholipid portion can comprise 100% ceramide, 100% phospholipids, or any other percent combination of ceramide and phospholipids. For example, the ceramide/phospholipid portion can comprise 95% ceramide and 5% phospholipids, 90% ceramide and 10% phospholipids, 85% ceramide and 15% phospholipids, or 80% ceramide and 20% phospholipids.
  • The ceramide component of the delivery system can be any ceramide or any mixture of ceramides. In this specification, ceramides include pseudoceramides and neoceramides.
  • For example, the ceramide may be any of ceramide 1-7; and/or mixtures thereof. Some specific examples of ceramides include ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, cerebrosides and ceramide 6B.
  • Some examples of pseudoceramides include:
    • N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide
    • N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide
    • N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide
    • N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide
    • N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide
    • N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide
    • N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide
    • N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide
    • N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide
    • N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide
    • N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide
    • N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide
    • N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide
    • N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide
    • N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
    • N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide
    • N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide
    • N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
    • N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide
    • N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide
    • N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide
    • N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide
    • N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide
    • N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide
    • N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide
    • N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide
    • N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide
    • N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide
    • N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide
    • N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide
    • N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide
    • N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide
    • N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide
      Some examples of neoceramides include:
    • N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-tetradecyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide
    • N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide
    • N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide
    • N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide
    • N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide
    • N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide
    • N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide
    • N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide
    • N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide
    • N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide
    • N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypropan-amide
    • N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide
    • N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide
    • N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutanamide
    • N-(2,3-dihydroxypropyl)-N-octadecyl)-(t)-O-linoleoyl-docosanamide
    • N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide
    • N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyidocosanamide
    • N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide
    • N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide
    • N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide
    • N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide
    • N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide
    • N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide
    • N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide
    • N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide
    • N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide
    • N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide
    • N-(2,3-dihydroxypropyl)-N-dodecyl)-2-hydroxyoctanamide
    • N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide
    • N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide
    • N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide
    • N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide
    • N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
  • The phospholipid component may contain any phospholipid or mixtures of phospholipids. Preferably the phospholipid component comprises phosphatidycholine (PC). Other examples of phospholipids include distearoylphosphatidylcholine (DSPC 18), phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, and phosphatidylethanolamine.
  • Additionally, the phospholipid component can comprise one or more lysophospholipids. Lysophospholipids are single chain phospholipids. Examples of lysophospholipids include lysophosphatidylcholines, such as monopalmitoylphosphatidylcholine (MPPC); lysophosphatidylglycerols; lysophosphatidylethanolamines; lysophosphatidylinositols; lysophosphatidylserines; and lysophosphatidic acid. Mixtures of different types of phospholipids and/or lysophospholipids can also be used.
  • In a preferred embodiment, the present system also comprises skin lipid precursors. The lipid precursors include any compound that promotes in situ cholesterol, ceramide or sphingolipid synthesis. The preferred lipid precursors are mevalonic acid, which promotes in situ cholesterol synthesis; and 25-hydroxycholecalciferol, which promotes in situ ceramide synthesis in the skin. Other preferred precursors are palmitoyl CoA and serine, which together are converted to 3-ketosphinganine, which promotes in situ ceramide synthesis in the skin.
  • By the promotion of in situ cholesterol and ceramide synthesis in the skin, the overall content of lipid in the system can be maintained in a range as low as approximately 2-20%. Therefore, the water content of the delivery system can be as high as 80-98%. The high water content enables the skin to “breathe” normally, and enhances its ability to restore its normal barrier function rapidly.
  • Other lipid precursors useful in the present invention include, for example: acylceramides; deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxysalicylic acid, N-acetylcysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, sphingosine, and others.
  • Preferably, an alkaline compound, or buffer system, is included in the formulation to adjust the pH. Examples of alkaline compounds include triethanolamine (TEA), sodium hydroxide, sodium acetate, and sodium bicarbonate. Examples of buffer systems include carbonic acid/potassium carbonate, phosphoric acid/potassium phosphate, and acetic acid/sodium acetate.
  • The fatty acids of the final delivery system can be in a free state or can form a salt. The portion of fatty acids which is in a free state is partially dependent on the pH of the formulation. In general, the level of free fatty acid increases as the pH of the formulation decreases. Depending upon the particular use of the formulation, the pH of the formulation can vary. Preferably, the pH of the formulation is about 6.5 to 7.8.
  • In a preferred embodiment, the delivery system comprises triethanolamine (TEA). It is preferred to adapt the molar ratio between the fatty acids and triethanolamine to enable a certain portion of the fatty acids in the final delivery system to form a triethanolaminium salt, while another portion of the acid exists as free fatty acid. Preferably, the delivery system is prepared from fatty acids and triethanolamine in which the molar ratio of the fatty acids to the triethanolamine is higher than about 2:1, preferably higher than about 3:1.
  • In a preferred embodiment, the delivery system comprises a combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and skin lipid precursors between about 2-20%. A preferred low end of this range is about 2%, 3%, 4%, 5%, 6%, 7% or 8%. A preferred high end of this range is about 13%, 14%, 15%, 16%, 17%, 18%, 19% and 20%.
  • In another preferred embodiment, the amounts of the components of the delivery system are as follows: fatty acid: 0.5-10%; cholesterol: 0.5-10%; a ceramide/phospholipid portion: 0.005-20%; and lipid precursors: 0.000001-10%.
  • In a preferred embodiment, the formulation does not contain any irritating ingredients. Examples of irritating ingredients include alcohols, such as isopropanol and ethanol; short chain fatty acids; and detergents. Preferably, the formulation contains less than 10% alcohol, more preferably less than 5% alcohol, most preferably less than 1% alcohol, and optimally no alcohol.
  • Without the intention to limit the scope of the invention, a possible theory explaining the mechanical properties of the delivery system follows. The administered formulation easily penetrates the lipid bilayer of the skin. In doing so, the system creates a temporary and reversible state of enhanced atrophy among the lipid components of the bilayer. The enhanced atrophy in itself then gives rise to either a) enhanced energy levels, wherein the energy could promote active transport of the to-be-carried substances into the skin, and/or b) creates naturally and reversibly occurring holes and disorganized patches in the lipid bilayer through which the active substances could then pass more easily. It is very well feasible that the temporary disarray in the lipid bilayer will temporarily break up the organized structure of the bilayer and create micelles of lipids with areas between them, or surrounding them, through which lipophobic/hydrophilic substances and/or compositions can enter through the stratum corneum. As the lipid composition of the formulation resembles the natural lipid composition of the skin, the so introduced new lipids will after a short time of creative chaos easily blend in with the natural lipid building stones of the lipid bilayer, and thus not permanently damage the barrier function of the skin.
  • Following the temporary disarray in the lipid bilayer, the normal barrier function of the cornea stratum rapidly returns. (That is, the skin barrier restoration is rapid.) The rapid return may be enhanced by the lipid precursors of the formulation. For example, the in situ promotion of cholesterol synthesis in the stratum corneum, the in situ promotion of ceramide synthesis in the stratum corneum, and/or the in situ promotion of sphingolipid synthesis in the stratum corneum may allow for the rapid skin barrier restoration.
  • A delivery system according to the present invention preferably comprises a combination of:
  •
    Fatty Acid (C16-24) 0.5-10%
    Phospholipid 0.5-10%
    Cholesterol 0.5-7% 
    Lipid precursor: 0.000001-10%   
    Mevalonic acid and/or
    25-Hydroxycholecalciferol
    Ceramide 0.005%-7%     
    (Not all components are present are 0%.)

    Another preferred embodiment of the delivery system comprises:
  • Fatty Acid (C16-24) 0.5-10%
    Phospholipid 0.5-10%
    Cholesterol 0.5-7% 
    Lipid precursor: 0.000001-10%   
    Mevalonic acid and/or
    25-Hydroxycholecalciferol
    Ceramide 0.005%-7%     
    Glycerine  0-5%
    Propylene glycol   0-48%
    PVP (e.g., M weight 40.000)  0-5%
    TEA  0-3%
    (Not all components are present are 0%.)

    An even more preferred embodiment of the delivery system comprises:
  • Fatty Acid (C16-24) 2%
    Phospholipid 4.5%  
    Cholesterol 2%
    Lipid precursor: 0.000001-10%
    Mevalonic acid and/or   1% or 0.01%
    25-Hydroxycholecalciferol 0.015% or 0.0015%
    Ceramide 3 0.015%   
    Glycerine 3%
    Propylene glycol 4%
    PVP (M weight 40.000) 2%
    TEA 0.5%  

    An even more preferred embodiment of the delivery system comprises:
  • Fatty Acid (C16-24) 2%
    Phospholipid 4.5%  
    Cholesterol 2%
    Lipid precursor: 0.000001-10%
    Mevalonic acid and/or   1% or 0.01%
    25-Hydroxycholecalciferol 0.015% or 0.0015%
    Ceramide 3 0.015%   
    Glycerine 3%
    Propylene glycol 4%
    PVP (M weight 40.000) 2%
    TEA 0.5%  
    Ceramide 1 0.025%   
  • The topical delivery system according to the present invention further comprises one or more cosmetically and/or therapeutically active substances. Active substances are defined as agents other than emollients and other than ingredients that merely improve the physical characteristics of the formulation.
  • Some general examples of active substances include sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants and vitamins. Therapeutically active substances include, but are not limited to, substances which treat conditions such as eczema, dry skin, itchy skin, fungal infection, acne, skin cancer, hair loss, louse infection, psoriasis, and skin lesions (i.e. wounds). Therapeutically active substances also include substances for transdermal delivery, for example, interleukin, hormones, vaccines, nicotine, interferon, pain killers, peptides, proteins and vitamins.
  • Active substances also include steroid hormones. Steroid hormones inhibit inflammation and hyperproliferation of the epidermis thus resulting in normalization of hypersensitive skin conditions. Examples of steroid hormones include, bat are not limited to, glucocorticoids, androgens and estrogens.
  • Examples of sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxybenzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively. The exact amount of sunscreen employed in the systems can vary depending upon the degree of protection desired from the sun's UV radiation.
  • Examples of vitamins include vitamin A and vitamin E, preferably in the form of an ester of a fatty acid, such as vitamin A palmitate (retinyl palmitate) and vitamin E linoleate (tocopheryl linoleate). Other esters of vitamins A and E may also be utilized, such as any of the fatty acids mentioned above and below.
  • Preservatives may also be included in the formulations of the present invention. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroxyacetate and benzyl alcohol. Preservatives are typically used in amounts up to about 2% by weight of the formulation.
  • Other adjunct minor components may also be incorporated into the formulations of the present invention. These components may include thickeners, coloring agents, opacifiers and perfumes. For example, any thickening agent can be included in the formulation to adjust the viscosity of the formulation. Examples of suitable thickening agents include glycerol and xanthan gum. Some additional adjunct minor components include chalk, talc, Fullers earth, kaolin, starch, smectites clays, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, aluminium starch octenyl succinate and mixtures thereof. Amounts of these adjunct minor components may range anywhere from 0.001 up to 20% by weight of the formulation (i.e. composition).
  • The delivery system can be in any form, such as a cream, a lotion, a gel, and an aerosol foam. The amount of certain adjunct minor components used in a particular formulation varies depending on the desired form of the delivery system, as would be known by a skilled artisan. For example, the amount of thickening agent used to prepare an aerosol foam formulation is about 10 to 20% of the amount used to prepare a cream formulation. Additionally, emulsifiers are added to an aerosol foam formulation, such as, for example, laureth 4.
  • In another embodiment, the present invention provides a mucosal delivery system formulated to deliver a substance to, or through, a human mucous membrane without permanently disturbing the integrity of the mucous membrane. The mucous membrane is the moist tissue that lines some organs and body cavities (such as nose, mouth, lungs, rectum, stomach and vagina) and secretes mucous. The mucosal delivery system comprises the lipophilic and hydrophilic components, as described above. The particular formulations of the mucosal delivery systems are varied to accommodate the particular environment of the mucosa, as would be known by a skilled artisan.
  • In a preferred embodiment, the lipophilic components of the topical or mucosal delivery system form three types of particles: gas spheres, vesicles, and lipid particles. These three types of particles are within a hydrophilic phase (i.e. aqueous medium). See FIG. 1.
  • The gas spheres are lipid monolayers that enclose air bubbles. These monolayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the outer surfaces of these gas spheres. See FIG. 2. Preferably, these gas spheres are approximately 1 μm to approximately 500 μm in diameter.
  • The vesicles are lipid bilayers enclosing a hydrophilic core. These bilayers are formed from the lipophilic components. Negatively charged carboxylate groups stud the inner and outer surfaces of the vesicles. See FIG. 3. The vesicles can range from approximately 0.02 μm to approximately 0.5 μm in diameter.
  • The lipid particles are lipid monolayers enclosing fatty acids. These monolayers are formed from the lipophilic components. See FIG. 3. The lipid particles are less than approximately 1 to approximately 150 μm in diameter. The lipid particles may be in the form of individual lipid particles, or the lipid particles may aggregate to form crystals.
  • The various particles of the delivery system provide microcompartments with different properties. Due to these different microcompartments, the delivery system can be used to deliver both hydrophilic and lipophilic active substances. For example, a water soluble active substance can be located in the hydrophilic core of the vesicles, or can be located in the hydrophilic phase of the system. A lipid soluble active substance can be located within the monolayer of the gas spheres, within the bilayer of the vesicles, or within the monolayer or within the core of the lipid particles. See FIG. 4.
  • Preferably, the delivery systems comprise three phases, i.e. a foam phase, a vesicle phase and a hydrophilic phase. The foam phase comprises the gas spheres and the lipid particles. The vesicle phase comprises the vesicles and the lipid particles. The hydrophilic phase comprises water and hydrophilic components.
  • In a preferred embodiment, the delivery system is produced from three portions (i.e. fractions), in particular a hydrophilic portion and two lipophilic portions. The two lipophilic portions comprise the lipophilic components as defined above. Both lipophilic portions are immersed in aqueous media. One portion is made into the foam phase. The other portion is made into the vesicle phase. The foam phase portion and the vesicle phase portion can be in a ratio from about 1:7 to about 7:1. Preferably, the foam phase portion and the vesicle phase portion are approximately equal in amount.
  • Preferably, the foam phase is formed by mixing the foam phase portion at about 65 to 85° C. The pH is set to the range of about 5.5 to 8.2. The mixing is performed under conditions so as to allow gas spheres to form.
  • Preferably, the vesicle phase is formed by gently mixing the vesicle phase portion at about 65 to 85° C. The pH is set to the range of about 5.5 to 8.2. After mixing, the vesicle phase portion is homogenized. Homogenization can be accomplished with, for example, a high pressure homogenizer or a sonicator. The pressure of the homogenizer can be set, for example, from about 10,000 to 40,000 psi. Preferably, the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum.
  • The lipid particles, and/or lipid particle crystals, form as a by-product of the formation of the foam phase and vesicle phase. In either the foam phase or vesicle phase, up to 30% of the lipophilic components can be in the form of lipid particles and/or lipid particle crystals.
  • The hydrophilic phase is formed by mixing together water soluble components with water (i.e. hydrophilic portion). Examples of water soluble components include propylene glycol, glycerol, polyvinylpyrrolidone, and thickeners, e.g., xanthan gum.
  • The foam phase, vesicle phase and hydrophilic phases are mixed together. Preferably, an equal amount of each phase is used in the formulation.
  • The foam phase, vesicle phase and hydrophilic phases can be mixed together in any order. For example, the foam phase and the vesicle phase can be first mixed together, and then the resulting mixture can be mixed with the hydrophilic phase. As another example, the foam phase can be first mixed with the hydrophilic phase, and then the vesicle phase can be added.
  • One or more active substances can be added to the foam phase portion, the vesicle phase portion, the hydrophilic portion, or a combination of these portions.
  • The specific components of a formulation, and the formulation process, can be varied to obtain delivery systems which allow for different rates of the release, and degrees of penetration, of active substance(s). For example, the phase of the system in which an active substance is placed affects release and penetration rates. For instance, to enhance penetration rates of either a hydrophilic or lipophilic active substance, a major portion of the active substance is placed within the vesicle phase portion.
  • Another factor which affects release and penetration rates is the size of the micro-compartments. The size of the vesicles can be controlled via the formulation process. For example, during processing, as the homogenizing pressure and duration increases, the vesicle size decreases.
  • An additional factor which affects release and penetration rates is the type of phospholipids used in the formulation. For example, penetration can be enhanced by including a greater portion of unsaturated phospholipids within the formulation.
  • Also, phospholipids which include elevated levels of surface active single chain agents enhance penetration. Surface active single chain agents at about a level of 2% to 10% of the phospholipids are considered to be at an elevated level. Examples of surface active agents are lysophospholipids
  • An example of a phospholipid formulation comprises 95% phosphatidylcholine and 1.2% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200 SH. A phospholipid formulation which provides enhanced penetration comprises 95% phosphatidylcholine and 3% lysophosphatidylcholine. Such a formulation is sold as EPIKURON® 200.
  • The concentration of free fatty acid is also an important parameter affecting penetration rates. A relatively high level of free fatty acid enhances penetration of hydrophilic active substances.
  • Penetration rates can also be enhanced by the addition of certain adjuvants. For example, an anionic surfactant can be added to the foam phase portion. Also, incorporation of glyceryidilaurate into the vesicle bilayers creates more flexible vesicles which can enhance penetration.
  • Additional factors which affect release and penetration rates include: the ratio between the different lipid components; the ratio between the foam phase, the vesicle phase and the hydrophilic phase; and the ratio between the amounts of active substances within each phase.
  • In one embodiment of the present invention, the lipophilic components of the delivery system form only two of the above-defined particles. That is, the formulation comprises only the gas spheres and lipid particles; or the formulation comprises only the vesicles and lipid particles.
  • In this embodiment, the delivery system is produced from a hydrophilic portion and a lipophilic portion. The lipophilic portion is made either into the foam phase or the vesicle phase, as described above. Preferably, the vesicle phase is produced under conditions which do not allow any gas to enter the formulation, such as in a vacuum. The foam phase or vesicle phase is mixed with the hydrophilic phase. Preferably, an equal amount of either the foam phase or vesicle phase, and the hydrophilic phase is used in the formulation.
  • Thus, while there have been described what are presently believed to be the preferred embodiments of the present invention, other and further embodiments, modifications, and improvements will be known to those skilled in the art, and it is intended to include all such further embodiments, modifications, and improvements and come within the true scope of the claims as set forth below.
    • EXAMPLES Example 1 A General Method of Making
  • The phospholipid, cholesterol, palmitic acid and ceramide components are mixed together with water, and agitated at a temperature of 70-80° C. The following additional components are added: mevalonic acid lactone, 25-hydroxycholecalciferol, propylene glycol, glycerine, PVP, TEA added along with water, and sodium hydroxide. Sodium hydroxide is added to adjust viscosity and stabilize the formulation. Water is then added, and the formulation is agitated well. The formulation is then cooled down.
  • An active substance can be dissolved in both the lipid phase and/or the water phase, depending on the solubility and concentration of the active substance.
    • Example 2 Formulation of a Preferred Embodiment of the Topical Delivery System
  • (An active ingredient is excluded from this formulation.)
  • Component Total amount
    Water 79.5% of formulation 
    Epikuron 200SH 3.5% of formulation
    Palmitic acid 1.5% of formulation
    Cholesterol 1.5% of formulation
    Mevalonic acid 0.01% of formulation 
    Triethanolamine 0.5% of formulation
    Phenonip 0.4% of formulation
    Xanthan gum 2.0% of formulation
    Skinflux 2.0% of formulation
    25-hydroxycholecalciferol 0.0015% of formulation  
    Propylene glycol 4.0% of formulation
    Glycerol 3.0% of formulation
    Polyvinylpyrrolidone 2.0% of formulation
    Epikuron 200SH are hydrogenated lecithins, i.e. phosphatidylcholine (PC).
    “Skinflux” is a blend product obtainable from Degussa Goldschmidt which contains: Ceramide 1, 3, 6II; Phytosphingosine; Cholesterol; Sodium Lauroyl Lactylate; Carbomer; and Xanthan Gum.
    Mevalonic acid lactone is a lipid precursor for cholesterol/fatty acids.
    25-Hydroxycholecalciferol is a lipid precursor for ceramides
    Xanthan Gum is a thickener (polysaccharide).
    PHENONIP ® is a preservative and a blend of parabens.
  • Three fractions, a vesicle fraction, a foam fraction and a hydrophilic fraction, are first prepared separately, as described below. Each fraction weighs 3.3 kg. Then the three fractions are mixed together. The following tables show the percent amount of each component contributed by each fraction to the final formulation. Thus, for each component, the sum of the percent amounts of all the fractions is 100%.
    • 1: Vesicle Fraction
  • Percent Amount in Final
    Component Formulation
    Water 33% of total water
    Hydrogenated lecithins 50% of total amount
    Palmitic acid 50% of total amount
    Cholesterol 50% of total amount
    Mevalonic acid 50% of total amount
    Triethanol amine 50% of total amount
    Preservative (e.g., Paraben mixture) 50% of total amount
    Xanthan gum 15% of total amount
    Skinflux 33% of total amount
    25-hydroxycholecalciferol 50% of total amount
    5M sodium hydroxide 1.3 ml per 1000 grams of water
    The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the vesicle fraction to the final formulation.
  • In forming the vesicle fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while gently stirring. The pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide. The resulting mixture is then homogenized. Homogenization can be accomplished by, for example, a homogenizer set at a high pressure (e.g. 10,000 to 40,000 psi); or by a sonicator. The size of the vesicles is partially dependent upon how long the resulting mixture is agitated. For example, to obtain an average vesicle size of 0.140 μm, the resulting mixture is agitated for 60 minutes at about 70° C. The mixture is then allowed to cool to below 40° C.
    • 2: Foam Fraction
  • Percent Amount in Final
    Component Formulation
    Water  33% of total water
    Hydrogenated lecithins  50% of total amount
    Palmitic acid  50% of total amount
    Cholesterol  50% of total amount
    Mevalonic acid  50% of total amount
    Triethanol amine  50% of total amount
    Preservative (e.g. a paraben mixture)  50% of total amount
    Xanthan gum 7.5% of total amount
    Skinflux  33% of total amount
    25-hydroxycholecalciferol  50% of total amount
    5M sodium hydroxide 1.3 ml per 1000 g of water
    The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the foam fraction to the final formulation.
  • In forming the foam fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while stirring. The pH is set to the range of 5.5 to 8.2 by the use of sodium hydroxide. The composition is mixed vigorously for 1 minute. Mixing can be done with ULTRATURRAX® from IKA Werke, Janke & Kunkel GmbH & Co KG (Staufen, Germany). The composition is then allowed to cool to below 40° C.
    • 3: Hydrophilic Fraction
  • Percent Amount in Final
    Component Formulation
    Water   34% of total water
    Propylene glycol  100% of total amount
    Glycerol  100% of total amount
    Polyvinylpyrrolidone  100% of total amount
    Xanthan gum 77.5% of total amount
    Skinflux   34% of total amount
    5M sodium hydroxide 3.0 ml per 1000 g of water
    The “Percent Amount in Final Formulation” indicates the percentage of each component which is contributed by the hydrophilic fraction to the final formulation.
  • In forming the hydrophilic fraction, the components are mixed and heated to the temperature range of 65 to 85° C. while stirring. The pH is set to the range of 5.5 to 8.2 by use of sodium hydroxide. Once homogeneous, the composition is then allowed to cool to below 40° C.
  • In forming the final formulation, after all the fractions are cooled down (below 40° C.), the three fractions are mixed together in any order. For example, the foam fraction is added to the vesicle fraction and gently mixed. Then the hydrophilic fraction is added. The resulting mixture is gently blended for several minutes to obtain a homogeneous solution.
  • The delivery system of this example is in the form of a cream. In order to produce a delivery system in an aerosol foam form, the total amount of xanthan gum in the final formulation is reduced from 2% to about 0.3%. Additionally, an emulsifier is added, such as laureth 4. Preferably, the emulsifier makes up about 0.7% of the final formulation.
    • Example 3 Formulation with Lidocaine as an Active Ingredient
  • An example of a 48 kg batch of a formulation of the delivery system follows. The three fractions used to prepare this formulation each contain 16 kg.
  • INCI Name Trade Name Supplier CAS Amount
    Hydrogenated Epikuron 200 SH Degussa 1.7 kg
    Lecithines Goldschmidt
    Cholesterol Vendico 57-88-5 0.8 kg
    Palmitic acid Karlshamn 57-10-3 0.8 kg
    Ceramide 1, 3, 6II, Skin Flux Degussa 1.0 kg
    Phytosphingosine, Goldschmidt
    Cholesterol,
    Sodium Lauroyl
    Lactylate,
    Carbomer, Xanthan
    Gum.
    Mevalonic acid Sigma Aldrich 674-26-0 4.8 g 
    lactone
    25-Hydroxy- Solvay 19356-17-3 0.72 kg 
    cholecalciferol
    Propylene glycol MB-Sveda 57-55-6 2.0 kg
    Glycerin, 99.5% Vendico 56-81-5 1.5 kg
    Polyvinylpyrrolidone Apoteket 9003-39-8 1.0 kg
    Xanthan gum Sigma Aldrich 11138-66-2 1.0 kg
    Triethanolamine, MB-Sveda 102-71-6 0.3 kg
    85%
    Phenonip Vendico 0.2 kg
    Chemical
    Lidocain USP-grade Apoteket 2.4 kg
    Purified Up to
    Water  48 kg
    • Example 4 Measurement of Skin Barrier Restoration
  • In the present context enhancing skin barrier restoration can be measured by tape and/or acetone striping of stratum corneum skin lipid content before, during and after a treatment period with the present invention and other systems. Then HPLC analysis of skin lipid content of stratum corneum is conducted.

Claims (80)

1. A water-based topical delivery system for an active substance, capable of enhancing skin barrier restoration in the stratum corneum comprising water; fatty acids; cholesterol; and a ceramide/phospholipid portion.
2. A delivery system according to claim 1 wherein the ratio of ceramide/phospholipid portion:cholesterol:fatty acid is approximately between 2:1:1 and 2.35:1:1.
3. A delivery system according to claim 1 further comprising at least one skin lipid precursor.
4. A delivery system according to claim 3 wherein the fatty acid is between 0.5-10%; the cholesterol is between 0.5-10%; the lipid precursors are between 0.000001-10%; and the ceramide/phospholipid portion is between 0.005-20%.
5. A delivery system according to claim 1 wherein the fatty acid comprises ten to twenty-four carbon atoms.
6. A delivery system according to claim 5 wherein the fatty acid comprises sixteen to eighteen carbon atoms.
7. A delivery system according to claim 1 wherein the fatty acid is lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, oleic acid, palmitoleic acid, linoleic acid, linolenic acid, arachidonic acid, precursors thereof, and/or unsaturated derivatives thereof, and/or mixtures thereof.
8. A delivery system according to claim 1, wherein said fatty acid is selected from a group consisting of linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
9. A delivery system according to claim 6 wherein the ceramide is ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, a cerebroside, ceramide 6B, a pseudoceramide, a neoceramide, or mixtures thereof.
10. A delivery system according to claim 9 wherein the pseudoceramide is
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide;
N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide;
N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide;
N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide; or N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide.
11. A delivery system according to claim 9 wherein the neoceramide is:
N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide;
N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)2-hydroxypropan-amide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutan-amide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-(t)-O-linoleoyl-docosanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide;
N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyldocosanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide;
N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide;
N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide;
N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide; or
N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
12. A delivery system according to claim 1, wherein said phospholipid is selected from a group consisting of phosphatidylcholine, DSPC 18, phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine and mixtures thereof.
13. A delivery system according to claim 12, wherein said phospholipid comprises at least one lysophospholipid.
14. A delivery system according to claim 13 wherein the lysophospholipid is selected from the group consisting of monopalmitoylphosphatidylcholine (MPPC), lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols, lysophosphatidylserines, lysophosphatidic acid, and mixtures thereof.
15. A delivery system according to claim 3 wherein the lipid precursor comprises mevalonic acid or 25-hydroxycholecalciferol.
16. A delivery system according to claim 3 wherein the lipid precursor comprises deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxy salicylic acid, N-acetyl cysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, or sphingosine.
17. A delivery system according to claim 1 further comprising triethanolamine.
18. A delivery system according to claim 1, wherein the water content exceeds 50%.
19. A delivery system according to claim 1, wherein the water content exceeds 75%.
20. A delivery system according to claim 1, wherein the water content exceeds 79%.
21. A delivery system according to claim 1, wherein the water content exceeds 90%.
22. A delivery system according to claim 3, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 2-20%.
23. A delivery system according to claim 3, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-20%.
24. A delivery system according to claim 3, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-15%.
25. A delivery system according to claim 3, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 6-13%.
26. A delivery system according to claim 3, comprising a combination of:
Fatty Acid 0.5-10% Phospholipid 0.5-10% Cholesterol 0.5-7%  Lipid precursor 0.000001-10%    Ceramide 0.005%-7%.    
27. A delivery system according to claim 26 wherein the lipid precursor is mevalonic acid.
28. A delivery system according to claim 26, further comprising
Glycerine 0-5% Propylene glycol  0-48% PVP (M weight 40.000) 0-5% TEA  0-3%.
29. A delivery system according to claim 26, further comprising
25-Hydroxycholecalciferol 0.015%  Acylceramides 0.025%.
30. A delivery system according to claim 26, wherein the lipid precursor comprises 0.01% of Mevalonic acid, 0.0015% 25-Hydroxycholecalciferol, or a combination of Mevalonic acid, and 25-Hydroxycholecalciferol.
31. A delivery system according to claim 3, wherein said skin barrier restoration is enhanced by in situ promotion of cholesterol synthesis in the stratum corneum.
32. A delivery system according to claim 3, wherein said skin barrier restoration is enhanced by in situ promotion of ceramide synthesis in the stratum corneum.
33. A delivery system according to claim 3, wherein said skin barrier restoration is enhanced by in situ promotion of sphingolipid synthesis in the stratum corneum.
34. A delivery system according to claim 1, wherein said system further comprises one or more therapeutically active substances selected from the group consisting of peptides, proteins, sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants, hormones, vaccines, nicotine, interferon, pain killers, vitamins; and substances which treat eczema, dry skin, itchy skin, fungal infections, acne, skin cancer, hair loss, louse infections, psoriasis, and skin lesions.
35. A delivery system according to claim 3, wherein the lipids of said system blend with the lipids present in the cornea stratum, resulting in a temporary and reversible atrophy in the lipid bilayer, thereby enhancing possibility for penetration of therapeutic substances delivered by the system.
36. A delivery system according to claim 3, wherein the system does not comprise alcohol.
37. A delivery system according to claim 36, wherein the alcohol is ethanol.
38. A delivery system according to claim 3, wherein the system comprises less than 10% alcohol.
39. A delivery system according to claim 38 wherein the alcohol is ethanol.
40. A topical delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, and gas spheres or vesicles.
41. A topical delivery system according to claim 40 further comprising at least one skin lipid precursor.
42. A topical delivery system for an active substance comprising water and lipophilic components, wherein the lipophilic components comprise fatty acids, cholesterol, and a ceramide/phospholipid portion, and wherein the lipophilic components are in the form of lipid particles, gas spheres and vesicles.
43. A topical delivery system according to claim 42 further comprising at least one skin lipid precursor.
44. A topical delivery system according to claim 40 wherein the diameter of the gas spheres is approximately 1 μm to 500 μm.
45. A topical delivery system according to claim 40 wherein the diameter of the vesicles is approximately 0.02 μm to 0.5 μm.
46. A topical delivery system according to claim 40 wherein the diameter of the lipid particles is approximately less than 1 μm to 150 μm.
47. A delivery system according to claim 41 wherein the fatty acid is between 0.5-10%; the cholesterol is between 0.5-10%; the lipid precursors are between 0.000001-10%; and the ceramide/phospholipid portion is between 0.005-20%.
48. A delivery system according to claim 40 wherein the fatty acid comprises ten to twenty-four carbon atoms.
49. A delivery system according to claim 48 wherein the fatty acid comprises sixteen to eighteen carbon atoms.
50. A delivery system according to claim 40 wherein the fatty acid is lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, oleic acid, palmitoleic acid, linoleic acid, linolenic acid, arachidonic acid, precursors thereof, and/or unsaturated derivatives thereof, and/or mixtures thereof.
51. A delivery system according to claim 40, wherein said fatty acid is selected from a group consisting of linoleic acid, γ-linolenic acid, homo-γ-linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
52. A delivery system according to claim 43 wherein the ceramide is ceramide 1, ceramide 3, ceramide 4, ceramide 5, ceramide 6A, a cerebroside, ceramide 6B, a pseudoceramide, a neoceramide, or mixtures thereof.
53. A delivery system according to claim 52 wherein the pseudoceramide is
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxyoctadecyl)-N-(2-O-glucopyranosyl)ethylpentanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2butylhexanamide;
N-(2-hydroxyhexadecyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxydodecyl)-N-(2-hydroxyethyl)-2-hydroxyhexanamide;
N-(2-hydroxytetraadecyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyhexadecyl)-N-(2-sulfoethyl)hexadecanamide;
N-(2-hydroxyoctadecyl)-N-(2-phosphoethyl)butanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-nonanyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxyoctadecyl)-N-(2-hydroxyethyl)-2-hydroxypropanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-sulfohydroxyethyl)decanamide;
N-(2-hydroxy-3-decyloxypropyl)-N-(2-hydroxyethyl)hexanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)butanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-hydroxyethyl)co-o-linoleoyldocosanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-hydroxyethyl)-2-methylpropanamide;
N-(2-hydroxy-3-tetraadecyloxypropyl)-N-(2-hydroxyethyl)ethanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)heptanamide;
N-(2-hydroxy-3-hexadecyloxypropyl)-N-(2-phosphoethyl)hexadecanamide;
N-(2-hydroxy-3-dodecyloxypropyl)-N-(2-hydroxyethyl)propanamide;
N-(2-hydroxy-3-octadecyloxypropyl)-N-(2-)-glucopyranosyl)ethyl-2-hydroxypropanamide; or N-(2-hydroxy-3-octyloxypropyl)-N-(2-hydroxyethyl)pentanamide.
54. A delivery system according to claim 52 wherein the neoceramide is:
N-(2,3-dihydroxypropyl)-N-(hexadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-ethylhexadecyl)hexanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(hexadecyl)-2-hydroxyhexanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)octanamide;
N-(2-hydroxy-3-phosphopropyl)-N-(octadecyl)ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(hexadecyl)butanamide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(hexadecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(3-methylhexadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(6-dodecenyl)hexadecan-amide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxy-ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypropan-amide;
N-(2-hydroxy-3-O-glucopyranosylpropyl)-N-(heptadecyl)-ethanamide;
N-(2-hydroxy-3-sulfopropyl)-N-(dodecyl)heptanamide;
N-(2,3-dihydroxypropyl)-N-(tetradecyl)-4-hydroxybutan-amide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-(t)-O-linoleoyl-docosanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxy-heptan-amide;
N-(2,3-dihydroxypropyl)-N-iyiodecyl)-(t)-O-linoleoyldocosanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-3-hydroxybutanamide;
N-(2-phospho-3hydroxypropyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylheptadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethylheptadecyl)butanamide;
N-(2-sulfo-3-hydroxypropyl)-N-(1-octadecyl)ethanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)propanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)decanamide;
N-(2,3-dihydroxypropyl)-N-(3-ethyldodecyl)butanamide;
N-(2-O-glucopyranosyl-3-hydroxy propyl)-N-(heptadecyl)butanamide;
N-(2,3-dihydroxypropyl)-N-(oleyl)-2-hydroxypropanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(dodecyl)-2-hydroxyoctanamide;
N-(2,3-dihydroxypropyl)-N(hexadecyl)-2-methylheptanamide;
N-(2,3-dihydroxypropyl)-N-(octadecyl)-2-hydroxypentanamide;
N-(2,3-dihydroxypropyl)-N-(2-methylhexadecyl)-2-hydroxyheptanamide;
N-(2,3-dihydroxypropyl)-N-(linoleyl)-2-hydroxypropanamide; or
N-(2; 3-dihydroxypropyl)-N-(tetradecyl)ethanamide.
55. A delivery system according to claim 40, wherein said phospholipid is selected from a group consisting of phosphatidylcholine, DSPC 18, phosphatidic acid, inositol phosphate, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine and mixtures thereof.
56. A delivery system according to claim 55, wherein the phospholipids comprises at least one lysophospholipid.
57. A delivery system according to claim 56 wherein the lysophospholipid is selected from the group consisting of monopalmitoylphosphatidylcholine (WPC), lysophosphatidylcholines, lysophosphatidylglycerols, lysophosphatidylethanolamines, lysophosphatidylinositols, lysophosphatidylserines, lysophosphatidic acid, and mixtures thereof.
58. A delivery system according to claim 41 wherein the lipid precursor comprises mevalonic acid or 25-hydroxycholecalciferol.
59. A delivery system according to claim 41 wherein the lipid precursor comprises deoxyacetein cimifugoside, adapalene, adenosine, aloe derived lectins, 3-aminopropyl dihydrogen phosphate, anise extracts, ascorbic acid and derivatives thereof, ascorbyl palmitate, asiatic acid, benzoic acid derivatives, biotin, butanoyl betulinic acid, cathecholamines, coenzyme Q10, dehydrocholesterol, dehydroascorbic acid and derivatives thereof, estrogen and derivatives, eythrobic acid, genistein, lipoic acid, 4-methoxy salicylic acid, N-acetyl cysteine, panthetine, pregnenolone and derivatives, retinal, retinoates, retinal, retinyl acetate, retinyl glucuronate, retinyl linoleate, retinyl palmitate, retinyl proprionate, phytosphingosine, or sphingosine.
60. A delivery system according to claim 40 further comprising triethanolamine.
61. A delivery system according to claim 40, wherein the water content exceeds 50%.
62. A delivery system according to claim 40, wherein the water content exceeds 75%.
63. A delivery system according to claim 40, wherein the water content exceeds 79%.
64. A delivery system according to claim 40, wherein the water content exceeds 90%.
65. A delivery system according to claim 40, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 2-20%.
66. A delivery system according to claim 41, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-20%.
67. A delivery system according to claim 41, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 5-15%.
68. A delivery system according to claim 41, wherein the combined content of a fatty acid, cholesterol, a ceramide/phospholipid portion, and a skin lipid precursor in said system is between about 6-13%.
69. A delivery system according to claim 41, comprising a combination of:
Fatty Acid 0.5-10% Phospholipid 0.5-10% Cholesterol 0.5-7%  Lipid precursor 0.000001-10%    Ceramide 0.005%-7%.    
70. A delivery system according to claim 69 wherein the lipid precursor is mevalonic acid.
71. A delivery system according to claim 69, further comprising
Glycerine 0-5% Propylene glycol  0-48% PVP (M weight 40.000) 0-5% TEA  0-3%.
72. A delivery system according to claim 69, wherein the lipid precursor comprises 0.01% of Mevalonic acid; 0.0015% of 25-Hydroxycholecalciferol or a mixture of both.
73. A delivery system according to claim 41, wherein said skin barrier restoration is enhanced by in situ promotion of cholesterol synthesis in the stratum corneum.
74. A delivery system according to claim 41, wherein said skin barrier restoration is enhanced by in situ promotion of ceramide synthesis in the stratum corneum.
75. A delivery system according to claim 41, wherein said skin barrier restoration is enhanced by in situ promotion of sphingolipid synthesis in the stratum corneum.
76. A delivery system according to claim 40, wherein said system further comprises one or more therapeutically active substances selected from the group consisting of: peptides, proteins, sunscreens, tanning agents, skin anti-wrinkling agents, anti-dandruff agents, anti-acne agents, hair growth stimulants, hormones, vaccines, nicotine, interferon, pain killers, vitamins; and substances which treat eczema, dry skin, itchy skin, fungal infections, acne, skin cancer, hair loss, louse infections, psoriasis, and skin lesions.
77. A delivery system according to claim 40, wherein the system does not comprise alcohol.
78. A delivery system according to claim 77, wherein the alcohol is ethanol.
79. A delivery system according to claim 40, wherein the system comprises less than 10% alcohol.
80. A delivery system according to claim 79 wherein the alcohol is ethanol.
US12/082,406 2002-03-13 2008-04-09 Water-based delivery systems Abandoned US20090081139A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/082,406 US20090081139A1 (en) 2002-03-13 2008-04-09 Water-based delivery systems

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36505902P 2002-03-13 2002-03-13
US10/388,371 US20040009213A1 (en) 2002-03-13 2003-03-13 Water-based delivery systems
US12/082,406 US20090081139A1 (en) 2002-03-13 2008-04-09 Water-based delivery systems

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/388,371 Continuation US20040009213A1 (en) 2002-03-13 2003-03-13 Water-based delivery systems

Publications (1)

Publication Number Publication Date
US20090081139A1 true US20090081139A1 (en) 2009-03-26

Family

ID=28042008

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/388,371 Abandoned US20040009213A1 (en) 2002-03-13 2003-03-13 Water-based delivery systems
US12/082,406 Abandoned US20090081139A1 (en) 2002-03-13 2008-04-09 Water-based delivery systems
US12/290,455 Expired - Lifetime US8029810B2 (en) 2002-03-13 2008-10-30 Water-based delivery systems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/388,371 Abandoned US20040009213A1 (en) 2002-03-13 2003-03-13 Water-based delivery systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/290,455 Expired - Lifetime US8029810B2 (en) 2002-03-13 2008-10-30 Water-based delivery systems

Country Status (9)

Country Link
US (3) US20040009213A1 (en)
EP (1) EP1534213B1 (en)
JP (1) JP4806519B2 (en)
KR (1) KR101076335B1 (en)
AU (1) AU2003233396B2 (en)
CA (1) CA2476859C (en)
ES (1) ES2411656T3 (en)
NZ (1) NZ534377A (en)
WO (1) WO2003077861A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226491A1 (en) * 2002-03-13 2009-09-10 Thomas Skold Water-based delivery systems
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855048B1 (en) * 2003-05-19 2006-07-21 Oreal COMPOSITION COMPRISING A PHYTOSPHINGOSIN-BASED CERAMIDE PRECURSOR AND AN ACTIVATOR OF THE 4-HYDROXYLASE PATHWAY, USE FOR ENHANCING THE BARRIER FUNCTION OF THE SKIN
FR2855049B1 (en) * 2003-05-19 2006-07-21 Oreal COMPOSITION COMPRISING A 6-HYDROXY SPHINGENINE CERAMIDE PRECURSOR AND A 6-HYDROXYLASE PATH ACTIVATOR FOR USE IN ENHANCING THE BARRIER FUNCTION OF THE SKIN
FR2855047B1 (en) * 2003-05-19 2007-11-30 Oreal COMPOSITION COMPRISING A SPHINGOID BASE, AN ACTIVATOR OF THE 4-AND / OR 6-HYDROXYLASE PATHWAY AND A FATTY ACID, USE FOR ENHANCING THE BARRIER FUNCTION OF THE SKIN
WO2006133829A2 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Use of 25-hydroxy-vitamin d3
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
FR2901701B1 (en) * 2006-05-31 2010-10-29 Galderma Res & Dev COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE FILMOGENIC AGENT, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF
US20080152636A1 (en) * 2006-09-08 2008-06-26 Kaneka Corporation Composition containing reduced coenzyme Q10 and lysolecithin
JP5196833B2 (en) * 2007-04-07 2013-05-15 ヤヱガキ醗酵技研株式会社 Functional food ingredients and production methods
JP2009143897A (en) * 2007-11-19 2009-07-02 Neochemir Inc Therapeutic agent for pimple
WO2009101412A1 (en) * 2008-02-13 2009-08-20 Cipla Limited Topical pharmaceutical composition
KR20120129864A (en) 2009-08-21 2012-11-28 타겟티드 딜리버리 테크놀러지스 리미티드 Vesicular formulations
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
IT1403689B1 (en) 2011-02-07 2013-10-31 Dalmine Spa HIGH-RESISTANCE STEEL TUBES WITH EXCELLENT LOW TEMPERATURE HARDNESS AND RESISTANCE TO CORROSION UNDER VOLTAGE SENSORS.
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US9803256B2 (en) 2013-03-14 2017-10-31 Tenaris Coiled Tubes, Llc High performance material for coiled tubing applications and the method of producing the same
EP2789700A1 (en) 2013-04-08 2014-10-15 DALMINE S.p.A. Heavy wall quenched and tempered seamless steel pipes and related method for manufacturing said steel pipes
KR20160023682A (en) 2013-06-25 2016-03-03 테나리스 커넥션즈 리미티드 High-chromium heat-resistant steel
JP2016523903A (en) * 2013-07-01 2016-08-12 ネオファーム シーオー．， エルティーディー．Ｎｅｏｐｈａｒｍ Ｃｏ．， Ｌｔｄ． Multilayer emulsified transdermal drug delivery system
WO2015014965A1 (en) * 2013-07-31 2015-02-05 Pro Bono Bio International Trading Ltd Vesicles
GB201313735D0 (en) * 2013-07-31 2013-09-11 Pro Bono Internat Trading Ltd Vesicles
KR101509582B1 (en) * 2013-10-30 2015-04-14 한국콜마주식회사 COSMETIC COMPOSITION WITH ANTI-INFLAMMATORY IMPROVEMENT AND MOISTURIZING EFFECT CONTAINING γ-LINOLENIC ACID
EP3069712B1 (en) * 2013-11-17 2020-09-23 MEDRx Co., Ltd. Transdermal colloidal solution agent
EP3082758A4 (en) * 2013-12-18 2017-08-23 International Flora Technologies, Ltd. Human sebum mimetics derived from botanical sources and methods for making the same
JP6356446B2 (en) * 2014-03-14 2018-07-11 富士フイルム株式会社 Ceramide dispersion composition
KR101455684B1 (en) * 2014-04-29 2014-11-04 주식회사 씨엠에스랩 Emulsion type-cosmetic composition containing liquid crystal for improvement of skin barrier and skin regeneration effect
PL3316857T3 (en) 2015-06-30 2022-01-31 Sequessome Technology Holdings Limited Multiphasic compositions
US10137073B2 (en) * 2016-01-02 2018-11-27 L'oreal Cosmetic compositions comprising ceramides and cholesterol
KR101750238B1 (en) * 2016-04-27 2017-06-27 (주)네오팜 Compositions for anti-aging
KR101752312B1 (en) 2016-11-22 2017-06-29 주식회사 씨엠에스랩 Vesicles containing Saccharide isomerate, Hydrolyzed lupine protein and Intercorneocyte lipid mimetics, and Composition for Skin external application comprising the same
WO2018123003A1 (en) * 2016-12-28 2018-07-05 小林製薬株式会社 Topical composition for suppressing melanogenesis
KR101910962B1 (en) * 2017-01-05 2018-10-24 주식회사 마크로케어 Ceramide liquid crystal composition and Preparation Method Thereof
US10434554B2 (en) 2017-01-17 2019-10-08 Forum Us, Inc. Method of manufacturing a coiled tubing string
RU2746414C1 (en) * 2017-05-23 2021-04-13 ТиСиАй КО., ЛТД. Emulsified liposomal composition and method for its preparation
KR102485259B1 (en) 2018-03-27 2023-01-06 (주)아모레퍼시픽 Liquid lipid composite composition for improving hair condition
KR102078667B1 (en) * 2018-06-18 2020-02-19 주식회사 고운세상코스메틱 Cosmetic composition containg nanoemulsion encapsulated with 7-dehydrocholesterol, cholesterol and stearic acid in inner phase of hyaluronate-ceramide NP complex and manufacturing method thereof
JPWO2021182419A1 (en) 2020-03-09 2021-09-16
JP7406057B2 (en) * 2021-03-03 2023-12-27 東洋ビューティ株式会社 External microparticle capsule preparations and skin external preparations

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508703A (en) * 1982-02-17 1985-04-02 Parfums Christian Dior Production of pulverulent mixtures of lipidic and hydrophobic constituents
US5196190A (en) * 1990-10-03 1993-03-23 Zenith Technology Corporation, Limited Synthetic skin substitutes
US5206020A (en) * 1991-01-15 1993-04-27 Elizabeth Arden Company, Division Of Conopco, Inc. Synthetic pseudoceramide and cosmetic compositions thereof
US5468475A (en) * 1992-11-17 1995-11-21 Pola Chemical Industries Inc. Cosmetic composition with choline derivative
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5631012A (en) * 1994-09-02 1997-05-20 Shanni; David Cosmetic preparations for moisturizing human skin containing specific lipids
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5776480A (en) * 1994-12-14 1998-07-07 L'oreal Cosmetic or dermatological composition containing a mixture of ceramides for moisturizing the skin
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5993830A (en) * 1997-01-17 1999-11-30 Ponsus Ab Cosmetic skin preparation
US6153209A (en) * 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
US6497888B1 (en) * 1999-10-14 2002-12-24 L'ORéAL S.A. Process for limiting the penetration into the skin and/or the keratinous fibres of an active cosmetic and/or pharmaceutical agent
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6730288B1 (en) * 1998-09-11 2004-05-04 Connetics Australia Pty Ltd Mousse composition
US6824785B1 (en) * 2000-02-09 2004-11-30 C. Neil Kitson Skin treatment composition and methods of use
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4568703A (en) * 1984-07-27 1986-02-04 Bp Chemicals Limited Process for the production of polymers containing isocyanurate and or oxazolidone linkages
JPS62169711A (en) * 1986-01-22 1987-07-25 Shiseido Co Ltd Skin cosmetic
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
JPH0720857B2 (en) * 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
WO1992003122A1 (en) * 1990-08-24 1992-03-05 Gregor Cevc Preparation for application of active substances in the form of minimum-sized droplets
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
EP0644764B1 (en) * 1992-06-19 2000-05-17 The Regents of the University of California Lipids for epidermal moisturization and repair of barrier function
EP0711558A1 (en) 1994-10-21 1996-05-15 Unilever Plc Compositions for topical application to skin, hair and nails
MX9703184A (en) * 1994-11-04 1997-12-31 Polymun Scient Inmunbiologisch Application of superoxide dismutase in liposomes.
DE4439815C2 (en) 1994-11-08 2001-06-07 Mann & Hummel Filter Filters, in particular liquid filters
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IN184589B (en) * 1996-10-16 2000-09-09 Alza Corp
AU4919397A (en) * 1996-10-23 1998-05-15 Cellegy Pharmaceuticals, Inc. Method and compositions for disrupting the epithelial barrier function
IT1292142B1 (en) * 1997-06-12 1999-01-25 Maria Rosa Gasco PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLID LIPID MICROPARTICLES SUITABLE FOR PARENTERAL ADMINISTRATION
IT1296914B1 (en) * 1997-12-01 1999-08-03 Maria Rosa Gasco PHARMACEUTICAL COMPOSITION INCLUDING MICROPARTICLES SUITABLE FOR TRANSMUCOSAL PASSAGE AND OVERCOMING THE BARRIER
TR200101790T2 (en) * 1998-12-23 2001-10-22 Idea Ag. Formula developed for uncommon in vivo topical applications
DE19923246A1 (en) 1999-05-20 2000-12-07 Tyco Electronics Logistics Ag Ferrule for an optical fiber and method for attaching the ferrule to the optical fiber
KR19990078610A (en) 1999-07-03 1999-11-05 김현준 Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
KR100371491B1 (en) * 1999-07-27 2003-02-07 주식회사 두산 Cream Composition For Skin Care
US20040009213A1 (en) * 2002-03-13 2004-01-15 Thomas Skold Water-based delivery systems
US20050129722A1 (en) * 2002-03-13 2005-06-16 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508703A (en) * 1982-02-17 1985-04-02 Parfums Christian Dior Production of pulverulent mixtures of lipidic and hydrophobic constituents
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5196190A (en) * 1990-10-03 1993-03-23 Zenith Technology Corporation, Limited Synthetic skin substitutes
US5206020A (en) * 1991-01-15 1993-04-27 Elizabeth Arden Company, Division Of Conopco, Inc. Synthetic pseudoceramide and cosmetic compositions thereof
US5468475A (en) * 1992-11-17 1995-11-21 Pola Chemical Industries Inc. Cosmetic composition with choline derivative
US5534499A (en) * 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5631012A (en) * 1994-09-02 1997-05-20 Shanni; David Cosmetic preparations for moisturizing human skin containing specific lipids
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5776480A (en) * 1994-12-14 1998-07-07 L'oreal Cosmetic or dermatological composition containing a mixture of ceramides for moisturizing the skin
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5993830A (en) * 1997-01-17 1999-11-30 Ponsus Ab Cosmetic skin preparation
US6730288B1 (en) * 1998-09-11 2004-05-04 Connetics Australia Pty Ltd Mousse composition
US6153209A (en) * 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
US6497888B1 (en) * 1999-10-14 2002-12-24 L'ORéAL S.A. Process for limiting the penetration into the skin and/or the keratinous fibres of an active cosmetic and/or pharmaceutical agent
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6824785B1 (en) * 2000-02-09 2004-11-30 C. Neil Kitson Skin treatment composition and methods of use
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226491A1 (en) * 2002-03-13 2009-09-10 Thomas Skold Water-based delivery systems
US8029810B2 (en) 2002-03-13 2011-10-04 Thomas Skold Water-based delivery systems
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Also Published As

Publication number Publication date
JP2005522463A (en) 2005-07-28
KR101076335B1 (en) 2011-10-26
US20040009213A1 (en) 2004-01-15
KR20040091116A (en) 2004-10-27
EP1534213A2 (en) 2005-06-01
WO2003077861A2 (en) 2003-09-25
AU2003233396A1 (en) 2003-09-29
NZ534377A (en) 2008-04-30
CA2476859A1 (en) 2003-09-25
AU2003233396B2 (en) 2007-05-24
EP1534213B1 (en) 2013-04-24
US20090226491A1 (en) 2009-09-10
ES2411656T3 (en) 2013-07-08
EP1534213A4 (en) 2005-10-26
CA2476859C (en) 2011-09-20
WO2003077861A3 (en) 2005-03-24
JP4806519B2 (en) 2011-11-02
US8029810B2 (en) 2011-10-04

Similar Documents

Publication Publication Date Title
CA2476859C (en) Water-based delivery systems
JP3238264B2 (en) Cosmetic composition for salicylic acid dosing and its preparation
US6316428B1 (en) Topical moisturizing composition and method
CA1336762C (en) Method and composition for treating and preventing dry skin disorders
Cevc Drug delivery across the skin
ES2334207T3 (en) COMPOSITIONS THAT INCLUDE TOCOFEROL PHOSPHATE DERIVATIVES COMPLEXES.
KR100921959B1 (en) Multi-Emulsified Vesicles Comprising a Multi Lamellar Liposome and Phospholipid Monolayer Nanoliposomes
US11547665B2 (en) Multiphasic compositions
PT93935B (en) METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TOPAL TREATMENT OF ACNE VULGAR CONTAINING CETOCONAZOLE
WO2006039667A2 (en) Water-based delivery systems
KR20180131876A (en) Stabilized ceramide complex using liposome technology and manufacturing process thereof and cosmetic composition containing the same
US8546361B2 (en) Pseudolipid complex mixture and a skin external application composition containing same
US20150283080A1 (en) Stabilized dermatological delivery system for active ingredient compositions for topical administration to the skin
US20220257513A1 (en) Insoluble active substance carrier comprising transfersome
AU2007211879A1 (en) Water-based delivery systems
CA3147460C (en) Insoluble active substance carrier comprising transfersome
EP4180418A1 (en) Novel sphingolipid containing branched-chain fatty acid and use thereof
Li et al. Bioadhesive Liposomal Gel of Tetracaine with Enhanced Anaesthetic Activity Using Modern Permeation Enhancers: Optimization by Box-Behnken Statistical Design
KR20190085297A (en) Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: GALDERMA LABORATORIES, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENEX PHARMACEUTICALS, INC.;REEL/FRAME:022731/0739

Effective date: 20090427

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION